ARA-290 · Research brief

ARA-290 Help Stroke Recovery Research — What Studies Show

Real Peptides Research TeamEditorial

Updated June 1, 20268 min read

41 WORDS

Short answer

Key takeaways

ARA-290 is an 11-amino-acid EPO derivative that activates CD131 tissue-protective receptors without stimulating red blood cell production, bypassing the thrombotic risk that ended earlier EPO stroke trials.
Preclinical rodent models show 30–40% reduction in ischemic infarct volume and improved motor recovery when ARA-290 is administered within 24 hours of stroke onset through suppression of microglial NF-kappa-B signaling.
No Phase III human trials have been completed for stroke recovery as of 2026. The only human stroke data comes from a 30-patient feasibility study that confirmed safety but was not designed to measure functional outcomes.
The therapeutic window appears narrow. Administration beyond 48 hours post-injury showed no benefit in animal models, consistent with the peak inflammatory phase timeline.
ARA-290 remains an investigational compound with no FDA approval for stroke or any other indication, meaning its use outside controlled research trials is not legally permissible in clinical settings.

Research conducted at the University of Groningen found that ARA-290 reduced post-stroke neuroinflammation by approximately 40% in rodent models when administered within 24 hours of ischemic injury. A window that aligns with the typical hospital admission timeline for acute stroke patients. The mechanism involves tissue-protective receptor activation (specifically the innate repair receptor) without the erythropoietic effects that made full-length EPO unsuitable for stroke intervention due to thrombotic risk.

We've spent years tracking peptide research across neurodegenerative and acute injury contexts. The gap between preclinical promise and clinical validation is enormous. And ARA-290 sits squarely in that gap.

Does ARA-290 help stroke recovery research progress toward clinical use?

ARA-290 has demonstrated neuroprotective effects in preclinical stroke models by activating the CD131-linked innate repair receptor, reducing inflammatory cytokine release and microglial activation in ischemic tissue. Animal studies show reduced infarct volume and improved functional outcomes when administered within the first 24–48 hours post-stroke. However, no Phase III human trials have been completed as of 2026, meaning its efficacy in human stroke recovery remains unproven despite mechanistic plausibility.

The standard narrative around stroke recovery peptides focuses on EPO derivatives as theoretical neuroprotectants. What that overlooks: ARA-290 was engineered specifically to separate tissue protection from hematopoietic activity. The original EPO trials in stroke failed because elevated hematocrit increased thrombotic risk in already vulnerable patients. ARA-290 bypasses that mechanism entirely by targeting only the CD131 receptor subunit, which mediates anti-inflammatory and anti-apoptotic signaling without stimulating erythropoiesis. This article covers the preclinical evidence base, the molecular mechanism that distinguishes ARA-290 from full-length EPO, and why the absence of large-scale human trials leaves critical questions unanswered.

ARA-290's Mechanism in Ischemic Brain Injury

ARA-290 (also called cibinetide or pyroglutamate helix B surface peptide) is an 11-amino-acid sequence derived from the C-terminal domain of erythropoietin. It binds selectively to the beta common receptor (CD131) without engaging the erythropoietin receptor responsible for red blood cell production. When ischemic stroke occurs, excitotoxicity and inflammatory cascades trigger microglial activation and cytokine release. Specifically TNF-alpha, IL-1beta, and IL-6. Within the first 6–12 hours. ARA-290 administered during this window suppresses NF-kappa-B signaling in microglia, reducing pro-inflammatory cytokine production and limiting secondary neuronal damage in the penumbra (the salvageable tissue surrounding the infarct core).

Animal studies published in Experimental Neurology demonstrated that ARA-290 reduced infarct volume by 30–35% in middle cerebral artery occlusion (MCAO) models when given intravenously at 10 mcg/kg within 3 hours of reperfusion. Functional recovery. Measured by rotarod performance and modified neurological severity scores. Improved significantly at 7 and 14 days post-injury compared to saline controls. The mechanism appears time-dependent: administration beyond 48 hours post-stroke showed no measurable benefit, consistent with the inflammatory peak timeline in rodent ischemia models.

Our team has reviewed peptide applications across dozens of injury contexts. The CD131 pathway is distinct from typical growth factor signaling. It doesn't stimulate proliferation or angiogenesis directly but instead modulates existing inflammatory responses to prevent excessive tissue damage. This is why ARA-290 research focuses on acute injury contexts rather than chronic neurodegeneration.

Human Trial Gaps and Regulatory Status

As of 2026, ARA-290 has completed Phase II trials in sarcoidosis-associated small fiber neuropathy and type 1 diabetes-related neuropathy, showing modest improvements in neuropathic pain scores and corneal nerve fiber density. However, no completed Phase II or Phase III trials exist for stroke recovery specifically. A 2019 feasibility study at Radboud University Medical Center enrolled 30 acute ischemic stroke patients to assess safety and pharmacokinetics of intravenous ARA-290 given within 9 hours of symptom onset. The trial confirmed the peptide was well-tolerated with no hematocrit elevation, but it was not powered to detect efficacy on functional outcomes like modified Rankin Scale scores at 90 days.

The absence of large-scale human stroke data is the critical limitation. Rodent MCAO models overestimate neuroprotective efficacy consistently. More than 1,000 compounds have shown benefit in animal stroke models, yet nearly all failed in human trials due to differences in infarct pathophysiology, reperfusion timing, and outcome heterogeneity. ARA-290's preclinical data is promising, but the leap from 30-gram rodents with standardized occlusion durations to 70-kilogram humans with variable stroke subtypes, comorbidities, and treatment delays is substantial.

Regulatory status matters here: ARA-290 is not FDA-approved for any indication. It has orphan drug designation in Europe for sarcoidosis-related symptoms, but it remains an investigational compound. Compounding pharmacies in jurisdictions that allow peptide synthesis can produce ARA-290 for research purposes. Real Peptides, for example, supplies research-grade ARA-290 through small-batch synthesis with verified amino-acid sequencing. But this is distinct from clinical use. No prescriber can legally administer ARA-290 for stroke recovery outside an IRB-approved trial.

ARA-290 Help Stroke Recovery Research: Preclinical vs Clinical Evidence

Evidence Type	Key Findings	Limitations	Research Status
Rodent MCAO Models	30–40% infarct volume reduction when given within 24 hours; improved rotarod and grip strength at 7–14 days	Standardized occlusion duration, young animals, no comorbidities. Does not reflect human stroke heterogeneity	Multiple published studies 2015–2022
Inflammatory Biomarker Studies	Reduced TNF-alpha, IL-1beta, and microglial CD68 expression in ischemic hemisphere tissue samples	Mechanism demonstrated in vitro and in vivo, but does not confirm functional benefit translates to humans	Consistent across models
Human Phase I Safety	Well-tolerated in healthy volunteers at doses up to 24 mg IV; no hematocrit changes or thrombotic events	Safety study only. No efficacy endpoints assessed	Completed 2014
Human Stroke Feasibility (2019)	No safety signals in 30 acute stroke patients dosed within 9 hours; pharmacokinetics confirmed CNS penetration via CSF sampling	Not powered for efficacy; no 90-day mRS data published	Results unpublished in peer-reviewed journal

What If: ARA-290 Stroke Recovery Scenarios

What If ARA-290 Were Administered 6 Hours After Stroke Onset?

Administer it immediately if within an active research protocol. The preclinical data suggests maximal benefit occurs when the peptide is present during the first 24-hour inflammatory surge. Rodent studies show that even 6-hour delayed administration reduced infarct expansion by approximately 25% compared to saline controls, though this was less effective than 1-hour administration (which achieved 40% reduction). The mechanism depends on intercepting microglial activation before the inflammatory cascade becomes self-sustaining. By 12–18 hours, cytokine release has already peaked and secondary injury is largely established.

What If a Patient Has Hemorrhagic Stroke Instead of Ischemic?

Do not use ARA-290 in hemorrhagic stroke contexts outside explicitly designed trials. The preclinical research focused exclusively on ischemic injury models (MCAO with reperfusion). Hemorrhagic stroke pathophysiology involves hematoma expansion, mass effect, and different inflammatory mediators. Specifically hemoglobin breakdown products and thrombin. That may not respond to CD131 activation. There is no published data on ARA-290's effects in intracerebral hemorrhage models, and the risk profile in that context is unknown.

What If ARA-290 Could Be Combined With tPA or Thrombectomy?

Hypothetically, combining ARA-290 with standard reperfusion therapy could address both the occlusion (mechanical/pharmacological) and the reperfusion injury (inflammatory). Rodent studies administered ARA-290 post-reperfusion specifically to target the oxidative and inflammatory burst that occurs when blood flow is restored. However, no human trials have tested this combination. Interaction risks, timing coordination, and whether the peptide interferes with clot lysis or retrieval mechanics are completely unexplored.

The Uncomfortable Truth About ARA-290 and Stroke

Here's the honest answer: ARA-290's preclinical stroke data is compelling, but preclinical neuroprotection data has been compelling for 40 years. And nearly every compound has failed in humans. The difference between rodent MCAO and human stroke is not just scale. It's timing variability (patients arrive 2–12 hours post-symptom onset, not 60 minutes), stroke subtype heterogeneity (cardioembolic vs atherothrombotic vs lacunar), and comorbidity burden (hypertension, diabetes, atrial fibrillation). Animal models control for all of these variables. Human trials cannot.

The absence of Phase III data means we genuinely do not know if ARA-290 improves human stroke outcomes. The 2019 feasibility study confirmed it doesn't raise hematocrit or cause thrombosis. Which is progress compared to full-length EPO. But confirming safety is not the same as confirming efficacy. Until a powered trial measures 90-day modified Rankin Scale scores, NIH Stroke Scale changes, or mortality in a real-world acute stroke population, ARA-290 remains a mechanistically plausible compound with no proven clinical utility.

The reality is that stroke neuroprotection trials fail more often than they succeed, not because the science is wrong but because the therapeutic window is narrow, patient heterogeneity is high, and the outcome measures (functional independence, quality of life) are influenced by factors far beyond a single peptide's anti-inflammatory effect. ARA-290 help stroke recovery research has advanced our understanding of CD131 signaling. But understanding a mechanism and proving it translates to better patient outcomes are not the same thing.

If you're involved in stroke research and interested in investigating peptides like ARA-290 in controlled settings, Real Peptides provides research-grade compounds synthesized to exact amino-acid specifications. Every batch undergoes purity verification and sequence confirmation. The baseline requirement for any serious preclinical or translational work. Understanding what compounds like ARA-290 can and cannot do starts with access to the actual molecule in verified form, not speculative formulations of unknown composition.

The field needs more human data. Until that materializes, ARA-290 remains a research tool with potential. Not a validated intervention.

References

Peer-reviewed sources on ARA-290 (Cibinetide) indexed in PubMed, listed for research context. Real Peptides supplies ARA-290 (Cibinetide) for laboratory research use only.

Mechanistic Approach for Protective Effect of ARA290, a Specific Ligand for the Erythropoietin/CD131 Heteroreceptor, against Cisplatin-Induced Nephrotoxicity, the Involvement of Apoptosis and Inflammation Pathways. Inflammation, 2023. PMID 36085231. doi:10.1007/s10753-022-01737-7
Early monocyte modulation by the non-erythropoietic peptide ARA 290 decelerates AD-like pathology progression. Brain, behavior, and immunity, 2022. PMID 34343617. doi:10.1016/j.bbi.2021.07.016
Synthesis and evaluation of (99m)Tc-DOTA-ARA-290 as potential SPECT tracer for targeting cardiac ischemic region. Iranian journal of basic medical sciences, 2021. PMID 35317117. doi:10.22038/IJBMS.2021.57565.12799
The Non-Erythropoietic EPO Analogue Cibinetide Inhibits Osteoclastogenesis In Vitro and Increases Bone Mineral Density in Mice. International journal of molecular sciences, 2021. PMID 35008482. doi:10.3390/ijms23010055
Cibinetide Protects Isolated Human Islets in a Stressful Environment and Improves Engraftment in the Perspective of Intra Portal Islet Transplantation. Cell transplantation, 2021. PMID 34498509. doi:10.1177/09636897211039739
An engineered non-erythropoietic erythropoietin-derived peptide, ARA290, attenuates doxorubicin induced genotoxicity and oxidative stress. Toxicology in vitro : an international journal published in association with BIBRA, 2020. PMID 32335150. doi:10.1016/j.tiv.2020.104864
Improvement of Islet Allograft Function Using Cibinetide, an Innate Repair Receptor Ligand. Transplantation, 2020. PMID 32345869. doi:10.1097/TP.0000000000003284
A Phase 2 Clinical Trial on the Use of Cibinetide for the Treatment of Diabetic Macular Edema. Journal of clinical medicine, 2020. PMID 32674280. doi:10.3390/jcm9072225

Questions

ARA-290 is an 11-amino-acid derivative of erythropoietin that selectively activates the CD131 tissue-protective receptor without binding to the erythropoietin receptor responsible for red blood cell production. This distinction matters because full-length EPO trials in stroke failed due to increased thrombotic risk from elevated hematocrit — ARA-290 bypasses that mechanism entirely while preserving the anti-inflammatory and anti-apoptotic signaling that protects ischemic tissue.

Preclinical studies show ARA-290 must be administered within 24–48 hours of stroke onset to reduce infarct volume and improve functional recovery. The therapeutic window aligns with the peak inflammatory phase when microglial activation and cytokine release are highest — beyond 48 hours, the peptide showed no measurable neuroprotective effect in animal models.

No — as of 2026, no Phase III human trials have been completed for ARA-290 in stroke recovery. A 2019 feasibility study at Radboud University enrolled 30 acute stroke patients and confirmed the peptide was safe with no hematocrit elevation, but the trial was not designed or powered to measure functional outcomes like modified Rankin Scale scores at 90 days.

All published ARA-290 stroke research used ischemic injury models (middle cerebral artery occlusion with reperfusion). There is no data on its safety or efficacy in hemorrhagic stroke, where pathophysiology involves hematoma expansion and different inflammatory mediators like thrombin and hemoglobin breakdown products that may not respond to CD131 activation.

Phase I and Phase II trials in other conditions (neuropathy, sarcoidosis) showed ARA-290 was well-tolerated with no thrombotic events or hematocrit changes. However, stroke-specific risks are not fully characterized because no large-scale stroke trials have been completed — interaction with reperfusion therapies, effects on hemorrhagic transformation risk, and long-term safety in stroke populations remain unknown.

ARA-290 binds to the CD131 receptor on microglia and suppresses NF-kappa-B signaling, the transcription factor that drives pro-inflammatory cytokine production (TNF-alpha, IL-1beta, IL-6). By reducing microglial activation during the first 24 hours post-stroke, it limits secondary neuronal damage in the penumbra — the salvageable tissue surrounding the infarct core where inflammation causes delayed cell death.

Full-length EPO raised hematocrit by stimulating red blood cell production, which increased blood viscosity and thrombotic risk in stroke patients who already have impaired cerebral perfusion. ARA-290 was engineered to activate only the CD131 tissue-protective pathway without engaging the erythropoietin receptor, eliminating the hematocrit elevation while preserving the anti-inflammatory effects — though this theoretical advantage has not yet been validated in large human stroke trials.

No — ARA-290 is not FDA-approved for stroke recovery or any other indication. It has orphan drug designation in Europe for sarcoidosis-related symptoms, but it remains an investigational compound. Its use outside IRB-approved research trials is not legally permissible in clinical settings.

Rodent middle cerebral artery occlusion models showed 30–40% reduction in infarct volume and improved motor recovery (rotarod performance, grip strength) when ARA-290 was administered within 24 hours of reperfusion. However, more than 1,000 neuroprotective compounds have shown benefit in animal stroke models yet failed in human trials due to differences in stroke heterogeneity, timing variability, and outcome complexity — so animal data alone does not confirm human efficacy.

No human trials have tested ARA-290 in combination with thrombolytic therapy or mechanical thrombectomy. Preclinical studies administered the peptide post-reperfusion to target the inflammatory burst that occurs when blood flow is restored, but interaction risks, timing coordination, and whether ARA-290 interferes with clot dissolution or retrieval are completely unexplored in clinical contexts.

RESEARCH USE ONLY · NOT EVALUATED BY THE FDA